FUGA-BT cements role for gemcitabine plus S-1 in advanced biliary tract cancer
29 Oct 2019
byJairia Dela Cruz
The combination of gemcitabine plus S-1 (GS) is as good as gemcitabine plus cisplatin (GC), the current standard treatment for advanced biliary tract cancer (BTC), according to data from the phase III FUGA-BT trial (JCOG1113). However, the former does not require concomitant hydration therapy and should be considered a new treatment option for patients with advanced or recurrent BTC.